The Effect of Vitamin C on Quality of Life of Terminal Cancer Patients
NCT ID: NCT03224572
Last Updated: 2018-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
40 participants
INTERVENTIONAL
2018-01-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Vitamin D3 Supplementation in Advanced Cancer Patients With Pain
NCT05450419
Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study
NCT02877277
Vitamin C as an Anti-cancer Drug
NCT01080352
Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma
NCT02779465
Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation
NCT01447355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The study group
The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
high-dose vitamin C 30gm
High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
normal saline
500ml normal saline, once per week, and total 4-week treatment
The control group
The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
normal saline
500ml normal saline, once per week, and total 4-week treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
high-dose vitamin C 30gm
High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
normal saline
500ml normal saline, once per week, and total 4-week treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Nephrotic syndrome
* Creatinine over 1.5mg/dl
* Urolithasis
* Under other folk therapy or vitamin infusion therapy
* Those who can't exercise the right of consent
* Those who can't answer the questionaires
* Glucose-6-Phosphate Dehydrogenase Deficiency
* Severe lower leg edema or general edema
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chin-Ying Chen, MD, MHSc
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chin-Ying Chen
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201702008MIPB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.